1372 related articles for article (PubMed ID: 17470858)
1. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
Van Cutsem E; Peeters M; Siena S; Humblet Y; Hendlisz A; Neyns B; Canon JL; Van Laethem JL; Maurel J; Richardson G; Wolf M; Amado RG
J Clin Oncol; 2007 May; 25(13):1658-64. PubMed ID: 17470858
[TBL] [Abstract][Full Text] [Related]
2. FDA drug approval summary: panitumumab (Vectibix).
Giusti RM; Shastri KA; Cohen MH; Keegan P; Pazdur R
Oncologist; 2007 May; 12(5):577-83. PubMed ID: 17522246
[TBL] [Abstract][Full Text] [Related]
3. Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer.
Wu M; Rivkin A; Pham T
Clin Ther; 2008 Jan; 30(1):14-30. PubMed ID: 18343240
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on panitumumab in metastatic colorectal cancer.
Keating GM
BioDrugs; 2010 Aug; 24(4):275-8. PubMed ID: 20623992
[TBL] [Abstract][Full Text] [Related]
5. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.
Hecht JR; Patnaik A; Berlin J; Venook A; Malik I; Tchekmedyian S; Navale L; Amado RG; Meropol NJ
Cancer; 2007 Sep; 110(5):980-8. PubMed ID: 17671985
[TBL] [Abstract][Full Text] [Related]
6. U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Giusti RM; Shastri K; Pilaro AM; Fuchs C; Cordoba-Rodriguez R; Koti K; Rothmann M; Men AY; Zhao H; Hughes M; Keegan P; Weiss KD; Pazdur R
Clin Cancer Res; 2008 Mar; 14(5):1296-302. PubMed ID: 18316547
[TBL] [Abstract][Full Text] [Related]
7. Panitumumab: in the treatment of metastatic colorectal cancer.
Hoy SM; Wagstaff AJ
Drugs; 2006; 66(15):2005-14; discussion 2015-6. PubMed ID: 17100412
[TBL] [Abstract][Full Text] [Related]
8. A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer.
Kim TW; Elme A; Kusic Z; Park JO; Udrea AA; Kim SY; Ahn JB; Valencia RV; Krishnan S; Bilic A; Manojlovic N; Dong J; Guan X; Lofton-Day C; Jung AS; Vrdoljak E
Br J Cancer; 2016 Nov; 115(10):1206-1214. PubMed ID: 27736842
[TBL] [Abstract][Full Text] [Related]
9. Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer.
Hecht JR; Mitchell E; Neubauer MA; Burris HA; Swanson P; Lopez T; Buchanan G; Reiner M; Gansert J; Berlin J
Clin Cancer Res; 2010 Apr; 16(7):2205-13. PubMed ID: 20332321
[TBL] [Abstract][Full Text] [Related]
10. A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer.
Wang J; Zhao Z; Barber B; Sherrill B; Peeters M; Wiezorek J
Br J Cancer; 2011 Jun; 104(12):1848-53. PubMed ID: 21610704
[TBL] [Abstract][Full Text] [Related]
11. Integration of panitumumab into the treatment of colorectal cancer.
Gravalos C; Cassinello J; García-Alfonso P; Jimeno A
Crit Rev Oncol Hematol; 2010 Apr; 74(1):16-26. PubMed ID: 19616446
[TBL] [Abstract][Full Text] [Related]
12. Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer.
Kim TW; Elme A; Park JO; Udrea AA; Kim SY; Ahn JB; Valencia RV; Krishnan S; Manojlovic N; Guan X; Lofton-Day C; Jung AS; Vrdoljak E
Clin Colorectal Cancer; 2018 Sep; 17(3):206-214. PubMed ID: 29703606
[TBL] [Abstract][Full Text] [Related]
13. Panitumumab: in metastatic colorectal cancer with wild-type KRAS.
Weber J; McCormack PL
BioDrugs; 2008; 22(6):403-11. PubMed ID: 18998757
[TBL] [Abstract][Full Text] [Related]
14. Panitumumab: a review of its use in metastatic colorectal cancer.
Keating GM
Drugs; 2010 May; 70(8):1059-78. PubMed ID: 20481659
[TBL] [Abstract][Full Text] [Related]
15. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.
Van Cutsem E; Siena S; Humblet Y; Canon JL; Maurel J; Bajetta E; Neyns B; Kotasek D; Santoro A; Scheithauer W; Spadafora S; Amado RG; Hogan N; Peeters M
Ann Oncol; 2008 Jan; 19(1):92-8. PubMed ID: 17785764
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.
Sartore-Bianchi A; Moroni M; Veronese S; Carnaghi C; Bajetta E; Luppi G; Sobrero A; Barone C; Cascinu S; Colucci G; Cortesi E; Nichelatti M; Gambacorta M; Siena S
J Clin Oncol; 2007 Aug; 25(22):3238-45. PubMed ID: 17664472
[TBL] [Abstract][Full Text] [Related]
18. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.
Peeters M; Siena S; Van Cutsem E; Sobrero A; Hendlisz A; Cascinu S; Kalofonos H; Devercelli G; Wolf M; Amado RG
Cancer; 2009 Apr; 115(7):1544-54. PubMed ID: 19189371
[TBL] [Abstract][Full Text] [Related]
19. [Panitumumab].
Musch A
Med Monatsschr Pharm; 2008 Apr; 31(4):122-6. PubMed ID: 18497243
[TBL] [Abstract][Full Text] [Related]
20. Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer.
Saadeh CE; Lee HS
Ann Pharmacother; 2007 Apr; 41(4):606-13. PubMed ID: 17355997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
